What is the sentiment of this news? Please choose an answer from {strong negative/moderately negative/mildly negative/neutral/mildly positive/moderately positive/strong positive}.

New reimbursement agreements in ex-U.S. markets and label expansions to younger age groups are driving sales of Vertex's (VRTX) triple therapy cystic fibrosis drug, Trikafta/Kaftrio higher.
moderately positive